Mass General Cancer Center

Stay updated on the latest in cancer treatment with our comprehensive clinical review of advances in immuno-oncology. Learn about molecularly-targeted therapies and immune system mobilization. Plus, join our optional session on managing immunotherapy toxicities, "Sink or Swim," for an in-depth look at common and uncommon toxicities. Register now: http://spklr.io/6041Shd1. #CancerTreatment #ImmunoOncology #MedicalEducation

Mass General Brigham is operational. Mass General Cancer Center is open and seeing patients. All scheduled appointments and procedures will happen as planned on Monday, July 22.  𝐔𝐩𝐝𝐚𝐭𝐞: 𝐉𝐮𝐥𝐲 𝟏𝟗 - 𝟏𝟏:𝟎𝟏 𝐩.𝐦. Mass General Brigham mobilized incident command and other leadership teams across the organization to manage our response to the CrowdStrike incident. As part of this response, we have also deployed hundreds of technicians to our hospitals, healthcare centers, and outpatient clinics to restore access to the systems and devices that were impacted by the software failure early this morning. The hard work since the very early hours by our response teams and staff allowed our clinics and emergency departments to remain open today for those with urgent health concerns, in addition to the many patients currently admitted in our hospitals. We are doing everything possible to restore the electronic systems that support our patient care delivery across our system. Our teams will continue to work throughout the night to implement solutions and, at this time, we expect to be operational tomorrow. We apologize for the inconvenience that this has caused to the many patients who had scheduled visits with us today. ----------------------------------------------------------------- A major worldwide software outage has affected many of our systems at Mass General Brigham, as well as many major businesses across the country. Due to the severity of this issue, all previously scheduled non-urgent surgeries, procedures, and medical visits are cancelled today. Mass General Cancer Center remains open to provide care to patients with urgent health concerns in our clinics and emergency departments, and we continue to care for all patients currently receiving care in our hospitals. We have dedicated every available resource to resolve this issue as quickly as possible, and we apologize for the inconvenience this has caused our patients. It is our highest priority to ensure that our patients receive the safest care possible.

Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program, and Bryan Choi, MD, PhD, associate director of Brain Tumor Immunology and Immunotherapy, are changing the way glioblastoma is treated with a next generation CAR T therapy research study. They are infusing genetically modified white blood cells directly into the fluid surrounding the brain. The second patient in the trial, Tom Fraser from upstate New York, was given just six months to live before he was introduced to the trial. It has now been almost three years since his initial diagnosis. Read more about the trial and Tom's story from New York Magazine: http://spklr.io/6040SsK6

We are pleased to share that Massachusetts General Hospital is ranked #11 on the latest list of Best Hospitals for Cancer by U.S. News & World Report. A big thank you to all our physicians, nurses and staff who make a difference in our patients’ lives every day! Learn more about the latest cancer treatments and technologies being utilized at Mass General Cancer Center: http://spklr.io/6043SUH5

We are excited to share that our community location at Emerson Health in Concord, MA has a new linear accelerator (LINAC) offering a diverse range of high-precision radiation therapy treatment options, advanced imaging and more flexibility in patient setups. In this picture from left to right: Ron Neal, RTT, Lena Stamoulis, RTT, John McGrath, MD, medical director of the Massachusetts General Hospital Department of Radiation Oncology at Emerson Health and Maria Meimaris, RTT. http://spklr.io/6048S5jO

Stay at the forefront of prostate imaging with our one-day CME course, "State of the Art Imaging in the Diagnosis and Management of Prostate Cancer." Explore advances in mpMRI, MRI-ultrasound fusion biopsy, PSMA PET imaging and more. Ideal for urologists, radiologists, oncologists, and advanced practice providers. Register: http://spklr.io/6048S5Xs.

Should colon cancer screening start at age 40? The Gazette asked Mass General Cancer Center colorectal cancer experts, Ted Hong, MD, director of gastrointestinal service; Aparna Parikh, MD, medical director for the Center for Young Adult Colorectal Cancer; and Andrew Chan, MD, MPH, director of cancer epidemiology, if the screening age for colorectal cancer should be lowered from 45 to 40. Read the full article: http://spklr.io/6049S51V

What is CAR T-cell therapy? How does CAR T-cell therapy work? What cancers can be treated with CAR T-cell therapy? Learn the answers to these questions and more: http://spklr.io/6043SdwU

A new program led by Sophia McKinley, MD, MEd, surgical oncologist in the Division of Gastrointestinal and Oncologic Surgery, will offer robotic gastrectomy as an alternative to traditional laparoscopic techniques or open surgery. Read more: http://spklr.io/6048SK0C

"This triple combination is a promising new treatment option for patients with PIK3CA-mutated hr-positive, HER2-negative metastatic breast cancer" said lead investigator Dejan Juric, MD, director of Termeer Center for Targeted Therapies on his recent presentation at ASCO. http://spklr.io/6040SJ6e